NTRK Alterations in pediatric high-risk malignancies identified through European clinical sequencing programs constitute promising drug targets

Elke Pfaff; Tiphaine Adam de Beaumais; Antonin Marchais; Cornelis M. van Tilburg; Mirjam Blattner-Johnson; Uta Dirksen; Ingrid Ora; Birgit Geoerger; Gudrun Schleiermacher; Stefan M. Pfister; Olaf Witt; David T.W. Jones; Gilles Vassal

doi:10.1200/PO.20.00417

NTRK Alterations in pediatric high-risk malignancies identified through European clinical sequencing programs constitute promising drug targets

Elke Pfaff, Tiphaine Adam de Beaumais, Antonin Marchais, Cornelis M. van Tilburg, Mirjam Blattner-Johnson, Uta Dirksen, Ingrid Ora, Birgit Geoerger, Gudrun Schleiermacher, Stefan M. Pfister, Olaf Witt, David T.W. Jones, Gilles Vassal

Research output: Contribution to journal › Letter › peer-review

3 Citations (Scopus)

Original language	English
Pages (from-to)	450-454
Number of pages	5
Journal	JCO Precision Oncology
Volume	5
DOIs	https://doi.org/10.1200/PO.20.00417
Publication status	Published - 1 Feb 2021

Access to Document

10.1200/PO.20.00417

Cite this

Pfaff, E., de Beaumais, T. A., Marchais, A., van Tilburg, C. M., Blattner-Johnson, M., Dirksen, U., Ora, I., Geoerger, B., Schleiermacher, G., Pfister, S. M., Witt, O., Jones, D. T. W., & Vassal, G. (2021). NTRK Alterations in pediatric high-risk malignancies identified through European clinical sequencing programs constitute promising drug targets. JCO Precision Oncology, 5, 450-454. https://doi.org/10.1200/PO.20.00417

@article{b604ac3a0bd04c44b594e3e8ed85a000,

title = "NTRK Alterations in pediatric high-risk malignancies identified through European clinical sequencing programs constitute promising drug targets",

author = "Elke Pfaff and {de Beaumais}, {Tiphaine Adam} and Antonin Marchais and {van Tilburg}, {Cornelis M.} and Mirjam Blattner-Johnson and Uta Dirksen and Ingrid Ora and Birgit Geoerger and Gudrun Schleiermacher and Pfister, {Stefan M.} and Olaf Witt and Jones, {David T.W.} and Gilles Vassal",

year = "2021",

month = feb,

day = "1",

doi = "10.1200/PO.20.00417",

language = "English",

volume = "5",

pages = "450--454",

journal = "JCO Precision Oncology",

issn = "2473-4284",

}

Pfaff, E, de Beaumais, TA, Marchais, A, van Tilburg, CM, Blattner-Johnson, M, Dirksen, U, Ora, I, Geoerger, B, Schleiermacher, G, Pfister, SM, Witt, O, Jones, DTW & Vassal, G 2021, 'NTRK Alterations in pediatric high-risk malignancies identified through European clinical sequencing programs constitute promising drug targets', JCO Precision Oncology, vol. 5, pp. 450-454. https://doi.org/10.1200/PO.20.00417

TY - JOUR

T1 - NTRK Alterations in pediatric high-risk malignancies identified through European clinical sequencing programs constitute promising drug targets

AU - Pfaff, Elke

AU - de Beaumais, Tiphaine Adam

AU - Marchais, Antonin

AU - van Tilburg, Cornelis M.

AU - Blattner-Johnson, Mirjam

AU - Dirksen, Uta

AU - Ora, Ingrid

AU - Geoerger, Birgit

AU - Schleiermacher, Gudrun

AU - Pfister, Stefan M.

AU - Witt, Olaf

AU - Jones, David T.W.

AU - Vassal, Gilles

PY - 2021/2/1

Y1 - 2021/2/1

UR - http://www.scopus.com/inward/record.url?scp=85103177804&partnerID=8YFLogxK

U2 - 10.1200/PO.20.00417

DO - 10.1200/PO.20.00417

M3 - Letter

AN - SCOPUS:85103177804

SN - 2473-4284

VL - 5

SP - 450

EP - 454

JO - JCO Precision Oncology

JF - JCO Precision Oncology

ER -

NTRK Alterations in pediatric high-risk malignancies identified through European clinical sequencing programs constitute promising drug targets

Access to Document

Other files and links

Cite this